<h4>Purpose</h4>To assess the efficacy of neoadjuvant endocrine therapy in female HR-positive/HER2-negative breast cancer patients.<h4>Data and methods</h4>We identified female patients aged ≥18 years with cT1-4N0-XM0, HR(+), and HER2(-) breast cancer from the National Cancer Database. Here, ERBB2 is linked to breast cancer.